November 25, 2016 - By Adrian Mccoy · 0 Comments
The stock of Aurinia Pharmaceuticals Ord (NASDAQ:AUPH) registered a decrease of 24.33% in short interest. AUPH’s total short interest was 1.87M shares in November as published by FINRA. Its down 24.33% from 2.47 million shares, reported previously. With 1.23 million shares average volume, it will take short sellers 2 days to cover their AUPH’s short positions. The short interest to Aurinia Pharmaceuticals Ord’s float is 11.3%. The stock decreased 3.40% or $0.11 on November 23, hitting $3.13. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has risen 4.68% since April 22, 2016 and is uptrending. It has underperformed by 0.73% the S&P500.
Aurinia Pharmaceuticals Inc. is a Canada clinical-stage biopharmaceutical firm operating in the field of nephrology and autoimmunity. The company has a market cap of $121.43 million. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis . It currently has negative earnings. It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy